⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477841 | 1.00 | — | — | |
| SCHEMBL29990102 | 1.00 | — | — | |
| SCHEMBL140065 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL605748 | 0.97 | — | — | |
| Water SCHEMBL1333599 | 0.97 | — | — | |
| SCHEMBL6844415 | 0.91 | DPP4 (0.30) | — | |
| SCHEMBL29617116 | 0.83 | — | — | |
| SCHEMBL10363136 | 0.83 | — | — | |
| SCHEMBL12538862 | 0.78 | — | — | |
| SCHEMBL9798387 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928867-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | claimed |
| US-9409866-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20150344429-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2928867-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086805-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4630421-A1 | SYNTHESIS OF SULFOXIMINE COMPOUNDS HAVING A STEREOGENIC SULFUR ATOM | Syngenta Crop Protection AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240368147-A1 | CYCLIN K DEGRADER | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2024121335-A1 | SYNTHESIS OF SULFOXIMINE COMPOUNDS HAVING A STEREOGENIC SULFUR ATOM | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20030220358-A1 | A1 adenosine receptro antagonists | BIOGEN IDEC MA INC. | 2003-11-27 | — | — | US | disclosed |
| US-6605601-B2 | Hypotensive agents; cardiovascular disorders | BIOGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| WO-2003053370-A2 | NOVEL DEVELOPER COMPONENTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-07-03 | — | — | WO | disclosed |
| US-20020111333-A1 | A1 adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2002-08-15 | — | — | US | disclosed |
| CN-1053186-C | Quinolinoxazole compound | HUADONG SCIENCE & ENGINEERING (CN) | 2000-06-07 | — | — | CN | disclosed |
| CN-1201793-A | Quinolinoxazole compound | HUADONG SCIENCE & ENGINEERING (CN) | 1998-12-16 | — | — | CN | disclosed |